Anika Therapeutics, Inc. (NASDAQ:ANIK)
CAPS Rating:
The Company develops, manufactures and commercializes therapeutic products for tissue protection, healing and repair.
Get rich slowly
The Company develops, manufactures and commercializes therapeutic products for tissue protection, healing and repair.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
Anika has a very low market cap given the number and variety of products it is already marketing. Quarterly revenues have substantial potential for growth given planned launch of Monovisc in Europe this quarter and possible new marketing deal for Elevess this year. They have also made progress in their pipeline, recently initiating a pivotal US trial for Monovisc. All the recent news has been good, but the stock price has been dipping. There is almost no short interest and a reasonable financial bottom line, so it's hard to see any justification for the recent decline. 13 may not be the bottom, but it seems like a pretty nice entry point.